AJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, D. B.
Right arrow Articles by Darcy, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, D. B.
Right arrow Articles by Darcy, M. D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?

Chemoembolization of Hepatocellular Carcinoma: Patient Status at Presentation and Outcome over 15 Years at a Single Center

Daniel B. Brown1,2,3,4, William C. Chapman2,3, Ryan D. Cook1, Jason R. Kerr1, Jennifer E. Gould1,3, Thomas K. Pilgram1 and Michael D. Darcy1,2,3

1 Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO.
2 Department of Surgery, Washington University School of Medicine, St. Louis, MO.
3 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
4 Present address: Division of Cardiovascular and Interventional Radiology, Thomas Jefferson University Hospital, Ste. 4200, Gibbon Bldg., 111 S 11th St., Philadelphia, PA 19107.


Figure 1
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 1A —Survival period and time to progression for entire patient group. Graph shows median and mean overall survival times for group were 376 and 574 ± 61 days.

 

Figure 2
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 1B —Survival period and time to progression for entire patient group. Graph shows median and mean times to progression for group were 267 and 409 ± 54 days.

 

Figure 3
View larger version (12K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 2A —Strongest predictors of outcome. Graph shows overall survival based on Okuda score.

 

Figure 4
View larger version (15K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 2B —Strongest predictors of outcome. Graph shows time to progression based on American Joint Committee on Cancer Staging stage.

 

Figure 5
View larger version (7K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 3A —Evaluation of subgroup of patients with disease with both Okuda score of I and in American Joint Committee on Cancer stage I or II. Graph shows median and mean survival periods were 667 and 992 ± 176 days.

 

Figure 6
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 3B —Evaluation of subgroup of patients with disease with both Okuda score of I and in American Joint Committee on Cancer stage I or II. Graph shows median and mean overall times to progression were 378 and 589 ± 110 days.

 

Figure 7
View larger version (6K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 4 —Graph shows new referrals for hepatic arterial chemoembolization of hepatocellular carcinoma by year from 1991 to 2006.

 

Figure 8
View larger version (11K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 5A —Changes in presentation status over time according to standardized systems. Graph shows results for Child-Pugh class. Changes were not significant when evaluated with Pearson coefficient (p = 0.14).

 

Figure 9
View larger version (12K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 5B —Changes in presentation status over time according to standardized systems. Graph shows results for Okuda score. Changes were not significant when evaluated with Pearson coefficient (p = 0.14).

 

Figure 10
View larger version (15K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 5C —Changes in presentation status over time according to standardized systems. Graph shows results for Cancer of the Liver Italian Program score. Changes were not significant when evaluated with Pearson coefficient (p = 0.56).

 

Figure 11
View larger version (13K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 5D —Changes in presentation status over time according to standardized systems. Graph shows results for American Joint Committee on Cancer stage. Changes were not significant when evaluated with Pearson coefficient (p = 0.19).

 

Figure 12
View larger version (18K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 6A —Changes in outcome over time for entire group. Graph shows changes in overall survival period were not significant when evaluated with log-rank test (p = 0.64).

 

Figure 13
View larger version (18K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 6B —Changes in outcome over time for entire group. Graph shows changes in time to progression over time. Changes were not significant when evaluated with log-rank test (p = 0.45).

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Roentgen Ray Society.